Floatz logo

Finerenone

Nephrectomy

Jinling Hospital, ChinaSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Nephrectomy cohort.

Asset / SponsorPhaseRating
Empagliflozin
Jinling Hospital, China
Phase 2CCC

Same molecule, other indications

Finerenone is also rated in:

heart failureDormant
BB
Indicative ·
65 / 100
View asset →
diabetic kidney diseaseDormant
B
Indicative ·
62 / 100
View asset →
HyperkalemiaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →